News – CMS

2026-04-27

CMS Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

Iron IsomaltosideInjection (Monofer®) is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China, providing a better safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Iron Dextran Injection (Cosmofer®)is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the NEML. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, and will generateefficient synergies with the Group’s existing products across its key specialty areas, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics. China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive […]

Learn More

2026-04-23

CMS: NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

MG-K10, a long-acting anti-IL-4Rα humanized monoclonal antibody injection, enables once-every-4-weeks dosing (whereas currently marketed drugs targeting the same pathway require dosing once every 2 weeks), which may improve treatment adherence. It is also expected to become the first long-acting anti-IL-4Rα monoclonal antibody to be marketed globally, demonstrating BIC potential. In a Phase III clinical trial in adult patients with moderate-to-severe SAR, MG-K10 has met the primary endpoint, demonstrating significantly superior efficacy compared with the placebo group, with a favorable safety profile. The acceptance of the NDA represents an important milestone for CMS Vision(the ophthalmology business) in expanding its therapeutic focus from ophthalmology into the field of ENT, and also marks another significant milestone in the Group’s R&D progress in the field of type 2 inflammatory diseases. China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic […]

Learn More

2026-04-14

CMS Included in S&P Global Sustainability Yearbook (China Edition) for the Fourth Consecutive Year

S&P Global, an internationally recognized rating agency, recently released the Sustainability Yearbook (China Edition) 2026. China Medical System (“CMS” or the “Group”) stood out among nearly 1,800 companies and was successfully included for the fourth consecutive year, underscoring the Group’s long-term resilience and comprehensive strengths in sustainable development. （Source：S&P Global） CMS integrates the United Nations Sustainable Development Goals (“SDGs”) into the Group’s ESG strategy, guided by top-level planning, is driving a more sustainable transformation across the entire value chain. We are committed to improving accessibility and equity in healthcare, and continue to increase R&D investment in innovative medicines and treatments for rare diseases, addressing unmet clinical needs through scientific innovation. At the same time, we remain dedicated to inclusive healthcare, responding to societal needs through concrete actions and fulfilling the responsibilities expected of a pharmaceutical company. We also place strong emphasis on employee development and environmental protection, and steadily advance our responsible practices. The Group’s […]

Learn More

Company News

Latest News

CMS Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

CMS: NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

CMS Included in S&P Global Sustainability Yearbook (China Edition) for the Fourth Consecutive Year

All News